Table 1 Expression of CLDN6, MeCP2 and DNMT1 and clinicopathological characteristics in breast invasive ductal carcinoma patients

Breast invasive ductal carcinoma

100(100%)

25(25%)

75(75%)

< 0.001

88(88%)

12(12%)

< 0.001

69(69%)

31(31%)

0.001

Control

22(100%)

20 (91%)

2 (9%)

6 (27%)

16(73%)

7(32%)

15(68%)

Age (year)

≤ 40

20(20%)

5(25%)

15(75%)

1.000

16(80%)

4(20%)

0.251*

15(75%)

5(25%)

0.060

> 40

80(80%)

20(33%)

60(67%)

72(90%)

8(10%)

73(91%)

7(9%)

Tumour size(cm)

≤ 5

91(91%)

24(26%)

67(63%)

0.444*

80(88%)

11(12%)

1.000*

65(71%)

26(29%)

0.131

> 5

9 (9%)

1(11%)

8(89%)

8(89%)

1(11%)

4(44%)

5(56%)

Differentiation

well

25(25%)

9(36%)

16(64%)

0.142

21(84%)

4(16%)

0.488*

17(68%)

8(32%)

0.902

poor

75(75%)

16(21%)

59(79%)

67(89%)

8(11%)

50(67%)

25(33%)

Clinical stage

I

20(20%)

5(21%)

19(79%)

0.760

18(90%)

2(10%)

0.074*

10(50%)

10(50%)

0.113

II

46(46%)

10(22%)

36(78%)

37(80%)

9(20%)

35(76%)

11(24%)

III-IV

34(34%)

10(29%)

24(71%)

33(97%)

1(3%)

23(68%)

11(32%)

Lymph node metastasis

Positive

48(48%)

7(15%)

41(85%)

0.021

43(90%)

5(10%)

0.640

34(71%)

14(29%)

0.972

Negative

52(52%)

18(35%)

34(65%)

45(87%)

7(13%)

37(71%)

15(29%)